Table 3.

Current therapeutic strategies undergoing evaluation for the treatment of primary myelofibrosis.

  • Small-molecule inhibitors of JAK2V617F

  • TGF-β inhibitors

  • NFκB inhibitors

  • Chromatin-modifying agents

  • Protease inhibitors

  • Bcl-xL inhibitors

  • VEGF inhibitors

 

  • Small-molecule inhibitors of JAK2V617F

  • TGF-β inhibitors

  • NFκB inhibitors

  • Chromatin-modifying agents

  • Protease inhibitors

  • Bcl-xL inhibitors

  • VEGF inhibitors

 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal